Guardant Health Announces COSMOS Study Results Published In Clinical Cancer Research; Largest Study To Date Evaluating Tissue-Free MRD Detection Shows 81% Sensitivity For Recurrence In Stage II Or Higher Colon Cancer

+0.75% Pre

Guardant Health

0.00

Highlights Clinical Utility Of ctDNA For Rapid Evaluation Without Prior Tissue Analysis; Guardant Reveal Test Demonstrates High Sensitivity And Specificity In Predicting Colorectal Cancer Recurrence

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Will Hilton's New Diamond Reserve Tier and Loyalty Upgrades Shift Hilton Worldwide’s (HLT) Investment Narrative?

Should ICE’s (ICE) Launch of IRM 2 Transform Portfolio Risk Management for Energy Market Participants?

Peering Into Shopify Inc's Recent Short Interest

P/E Ratio Insights for Genuine Parts

Lowe's Says Sales Will Stay Flat, Citing Uncertain Market Conditions

Joby Aviation (JOBY): Assessing Valuation After Recent Share Price Volatility

'US Warns South Africa Not to Issue G-20 Statement at Summit'- Bloomberg

Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday